Knowledge about buprenorphine and methadone among those receiving treatment for opioid dependence

References

• Amass L, Bickel WK, Crean JP, Blake J, Higgins ST. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology 1998; 136: 217–225
   PubMed Web of Science ®Google Scholar
• Amass L, Bickel WK, Higgins ST, Badger GJ. Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sciences 1994; 54: 1215–1228
   PubMed Web of Science ®Google Scholar
• Andrews S, Sorensen JL, Guydish J, Delucchi K, Greenberg B. Knowledge and attitudes about methadone maintenance among staff working in a therapeutic community. Journal of Maintenance in the Addictions 2005; 3: 47–59
   PubMedGoogle Scholar
• Aquilino WS. Interview mode effects in surveys of drug and alcohol use: A field experiment. Public Opinion Quarterly 1994; 58: 210–240
   Web of Science ®Google Scholar
• Bickel WK, Amass L, Crean JP, Badger GJ. Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology 1999; 146: 111–118
   PubMed Web of Science ®Google Scholar
• Brown CS, Wright RG, Christensen DB. Association between type of medication instruction and patients’ knowledge, side effects, and compliance. Hospital and Community Psychiatry 1987; 38: 55–60
   PubMedGoogle Scholar
• Cameron C. Patient compliance: Recognition of factors involved and suggestions for promoting compliance with therapeutic regimens. Journal of Advanced Nursing 1996; 24: 244–250
   PubMed Web of Science ®Google Scholar
• Caplehorn JRM, Drummer OH. Fatal methadone toxicity: Signs and circumstances, and the role of benzodiazepines. Australian and New Zealand Journal of Public Health 2002; 26: 358–363
   PubMed Web of Science ®Google Scholar
• Caplehorn JRM, Lumley TS, Irwig L. Staff attitudes and retention of patients in methadone maintenance programs. Drug and Alcohol Dependence 1998; 52: 57–61
   PubMed Web of Science ®Google Scholar
• Carter JC, Aimé AA, Mills JS. Assessment of bulimia nervosa: A comparison of interview and self-report questionnaire methods. International Journal of Eating Disorders 2001; 30: 187–192
   PubMed Web of Science ®Google Scholar
• Chapman KR, Walker L, Cluley S, Fabbri L. Improving patient compliance with asthma therapy. Respiratory Medicine 2000; 94: 2–9
   PubMed Web of Science ®Google Scholar
• Cochrane GM, Horne R, Chanez P. Compliance in asthma. Respiratory Medicine 1999; 93: 763–769
   PubMed Web of Science ®Google Scholar
• Darke S, Ross J, Hall W. Prevalence and correlates of the injection of methadone syrup in Sydney, Australia. Drug and Alcohol Dependence 1996; 43: 191–198
   PubMed Web of Science ®Google Scholar
• Dietze P, Jolley D, Fry CL, Bammer G, Moore D. When is a little knowledge dangerous? Circumstances of recent heroin overdose and links to knowledge of overdose risk factors. Drug and Alcohol Dependence 2006; 84: 223–230
   PubMed Web of Science ®Google Scholar
• Eisen SV. Assessment of subjective distress by patients’ self-report versus structured interview. Psychological Reports 1995; 76: 35–39
   PubMed Web of Science ®Google Scholar
• Eissenberg T, Johnson RE, Bigelow GE, Walsh SL, Liebson IA, Strain EC, et al. Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. Drug and Alcohol Dependence 1997; 45: 81–91
   PubMed Web of Science ®Google Scholar
• Ernst E, Bartu A, Popescu A, Ilett KF, Hansson R, Plumley N. Methadone-related deaths in Western Australia 1993–99. Australia and New Zealand Journal of Public Health 2002; 26: 364–370
   PubMed Web of Science ®Google Scholar
• Ezard N, Lintzeris N, Odgers P, Koutroulis G, Muhleisen P, Stowe A, et al. An evaluation of community methadone services in Victoria, Australia: Results of a client survey. Drug and Alcohol Review 1999; 18: 417–423
   Web of Science ®Google Scholar
• Fischer B, Chin AT, Kuo I, Kirst M, Vlahov D. Canadian illicit opiate users’ views on methadone and other opiate prescription treatment: An exploratory qualitative study. Substance Use and Misuse 2002; 37: 495–522
   PubMed Web of Science ®Google Scholar
• Gerlach R, Caplehorn JRM. Attitudes and beliefs of doctors prescribing methadone to addicts in Westfalen-Lippe region of Germany. Drug and Alcohol Review 1999; 18: 163–170
   Web of Science ®Google Scholar
• Gmel G. The effect of mode of data collection and of non-response on reported alcohol consumption: A split-sample study in Switzerland. Addiction 2000; 95: 123–134
   PubMed Web of Science ®Google Scholar
• Hill J, Bird H, Johnson S. Effect of patient education on adherence to drug treatment for rheumatoid arthritis: A randomised controlled trial. Annals of the Rheumatic Diseases 2001; 60: 869–875
   PubMed Web of Science ®Google Scholar
• Johnson RE, Strain EC, Amass L. Buprenorphine: How to use it right. Drug and Alcohol Dependence 2003; 70: S59–77
   PubMed Web of Science ®Google Scholar
• Jones L, Edge J, Love AC. The effect of educational intervention on pharmacists’ attitudes to substance misusers. Journal of Substance Use 2005; 10: 285–292
   Google Scholar
• Kehoe P, Wodak A. Patient satisfaction in a NSW public opioid pharmacotherapy clinic: Measurement and responses. National Drug and Alcohol Research Centre, University of New South Wales, SydneyAustralia 2004
   Google Scholar
• Kraus L, Augustin R. Measuring alcohol consumption and alcohol-related problems: Comparison of responses from self-administered questionnaires and telephone interviews. Addiction 2001; 96: 459–471
   PubMed Web of Science ®Google Scholar
• Ling W, Smith D. Buprenorphine: Blending practice and research. Journal of Substance Abuse Treatment 2002; 23: 87–92
   PubMed Web of Science ®Google Scholar
• Lintzeris N, Bath N. Subutex®—A Guide to Treatment. Reckitt Benckiser, SydneyAustralia 2000
   Google Scholar
• Lutfey KE, Wishner WJ. Beyond ‘compliance’ is ‘adherence’. Improving the prospect of diabetes care. Diabetes Care 1999; 22: 635–639
   PubMed Web of Science ®Google Scholar
• Odeh M, Oliven A, Bassan H. Morphine and severe dryness of the lips. Postgraduate Medical Journal 1992; 68: 303–304
   PubMed Web of Science ®Google Scholar
• Parr J, Greenfield T. Methadone maintenance treatment at Cairns Base Hospital: Client characteristics and client satisfaction. Alcohol, Tobacco & Other Drugs Service, Cairns Health Service District. Queensland Health, Australia 2000
   Google Scholar
• Preston A, Doverty M. The methadone handbook ed. (2nd ed.). Australian Drug Foundation, VictoriaAustralia 1999
   Google Scholar
• Rees TD. Oral effects of drug abuse. Critical Reviews in Oral Biology & Medicine 1992; 3: 163–184
   PubMedGoogle Scholar
• Rosenblum A, Magura S, Joseph H. Ambivalence toward methadone treatment among intravenous drug users. Journal of Psychoactive Drugs 1991; 23: 21–27
   PubMed Web of Science ®Google Scholar
• Santolaria-Fernandez FJ, Gomez-Sirvent JL, Gonzalez-Reimers CE, Batista-Lopez JN, Jorge-Hernandez JA, Rodriguez-Moreno F, et al. Nutritional assessment of drug addicts. Drug and Alcohol Dependence 1995; 38: 11–18
   PubMed Web of Science ®Google Scholar
• Sheridan J, Carson T, Aggleton M. Providing dental health services to drug users: Testing a model for a community pharmacy advice and referral scheme. Pharmaceutical Journal 2003; 271: 180–182
   Web of Science ®Google Scholar
• Stancliff S, Myers E, Steiner S, Drucker E. Beliefs about methadone in an inner-city methadone clinic. Journal of Urban Health 2002; 79: 571–577
   PubMed Web of Science ®Google Scholar
• Titsas A, Ferguson MM. Impact of opioid use on dentistry. Australian Dental Journal 2002; 47: 94–98
   PubMed Web of Science ®Google Scholar
• Van Ooijen M, Ivens UI, Johansen C, Skov T. Comparison of a self-administered questionnaire and a telephone interview of 146 Danish waste collectors. American Journal of Industrial Medicine 1997; 31: 653–658
   PubMed Web of Science ®Google Scholar
• Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: Extrapolating from the laboratory to the clinic. Drug and Alcohol Dependence 2003; 70: S13–27
   PubMed Web of Science ®Google Scholar
• Walsh SL, Preston KL, Bigelow GE, Stitzer ML. Acute administration of buprenorphine in humans: Partial agonist and blockade effects. Journal of Pharmacology and Experimental Therapeutics 1995; 274: 361–372
   PubMed Web of Science ®Google Scholar
• Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology and Therapeutics 1994; 55: 569–580
   PubMed Web of Science ®Google Scholar
• Ward J, Mattick RP, Hall W. The effectiveness of methadone maintenance treatment: An overview. Drug and Alcohol Review 1994; 13: 327–336
   PubMedGoogle Scholar
• Zador D, Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990–1995. Addiction 2000; 95: 77–84
   PubMed Web of Science ®Google Scholar
• Zador DA, Sunjic SD. Methadone-related deaths and mortality rate during induction into methadone maintenance, New South Wales, 1996. Drug and Alcohol Review 2002; 21: 131–136
   PubMed Web of Science ®Google Scholar